“Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis; to analyze the Prurisol Phase 2b data in Psoriasis; and, as additional funding becomes available, to commence work on new product formulations...
Notice P is mentioned before the idea of as additional funding becomes available. One can say these are just near term strategies, but it's clear on priorities. Now the big questions are where is the funding going to come from and why is B not yet partnered. And what's the hold up on BTD answer. These questions are what need to be answered soon.
News 
Market Data 
Discover 
AI
